Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRG-BR003: Adjuvant Paclitaxel With or Without Carboplatin in Triple-Negative Breast Cancer
NCT02488967Phase 3Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Jul 2015
- Primary completion
- Dec 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 3 trial of carboplatin in triple-negative breast cancer (TNBC), sponsored by NRG Oncology. Started Jul 2015; status: active, not recruiting.
02
Drugs
carboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02488967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02488967.